Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The inactivated EV71 vaccine is a prophylactic pharmaceutical agent designed to prevent Hand, Foot, and Mouth Disease (HFMD) caused by Enterovirus 71 (EV71), a significant public health concern primarily in the Asia-Pacific region. This vaccine utilizes inactivated, whole EV71 virus particles, often formulated with an adjuvant like aluminum hydroxide, to stimulate the body's immune system. Upon administration, the vaccine induces the production of specific neutralizing antibodies and T-cell responses against EV71, thereby providing immunity without causing the disease. Multiple organizations, predominantly in China, have developed and brought these vaccines to market, demonstrating high efficacy and safety in clinical trials, particularly in young children.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on inactivated EV71 vaccine.